Detalhe da pesquisa
1.
S100A6 Regulates Endothelial Cell Cycle Progression by Attenuating Antiproliferative Signal Transducers and Activators of Transcription 1 Signaling.
Arterioscler Thromb Vasc Biol
; 36(9): 1854-67, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27386938
2.
S100A1 DNA-based Inotropic Therapy Protects Against Proarrhythmogenic Ryanodine Receptor 2 Dysfunction.
Mol Ther
; 23(8): 1320-1330, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26005840
3.
S100A1 deficiency impairs postischemic angiogenesis via compromised proangiogenic endothelial cell function and nitric oxide synthase regulation.
Circ Res
; 112(1): 66-78, 2013 Jan 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-23048072
4.
The inotropic peptide ßARKct improves ßAR responsiveness in normal and failing cardiomyocytes through G(ßγ)-mediated L-type calcium current disinhibition.
Circ Res
; 108(1): 27-39, 2011 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-21106943
5.
G protein-coupled receptor kinase-5 attenuates atherosclerosis by regulating receptor tyrosine kinases and 7-transmembrane receptors.
Arterioscler Thromb Vasc Biol
; 32(2): 308-16, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22095977
6.
Aging-related atherosclerosis is exacerbated by arterial expression of tumor necrosis factor receptor-1: evidence from mouse models and human association studies.
Hum Mol Genet
; 19(14): 2754-66, 2010 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20421368
7.
Gene Therapy as the New Frontier for Sickle Cell Disease.
Curr Med Chem
; 29(3): 453-466, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-34047257
8.
Myocardial injury after ischemia-reperfusion in mice deficient in Akt2 is associated with increased cardiac macrophage density.
Am J Physiol Heart Circ Physiol
; 301(5): H1932-40, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21890689
9.
A systems pharmacology model for gene therapy in sickle cell disease.
CPT Pharmacometrics Syst Pharmacol
; 10(7): 696-708, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34139105
10.
Beta-arrestins regulate atherosclerosis and neointimal hyperplasia by controlling smooth muscle cell proliferation and migration.
Circ Res
; 103(1): 70-9, 2008 Jul 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-18519945
11.
Tumor necrosis factor receptor-2 signaling attenuates vein graft neointima formation by promoting endothelial recovery.
Arterioscler Thromb Vasc Biol
; 28(2): 284-9, 2008 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-18006858
12.
Expression of tumor necrosis factor receptor-1 in arterial wall cells promotes atherosclerosis.
Arterioscler Thromb Vasc Biol
; 27(5): 1087-94, 2007 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-17442899
13.
Activation of vascular smooth muscle cells by TNF and PDGF: overlapping and complementary signal transduction mechanisms.
Cardiovasc Res
; 65(3): 674-82, 2005 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15664394
14.
Overexpression of wild-type Galpha(i)-2 suppresses beta-adrenergic signaling in cardiac myocytes.
FASEB J
; 17(3): 523-5, 2003 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-12631586
15.
Graft-extrinsic cells predominate in vein graft arterialization.
Arterioscler Thromb Vasc Biol
; 24(3): 470-6, 2004 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-14726410
16.
Vein graft neointimal hyperplasia is exacerbated by tumor necrosis factor receptor-1 signaling in graft-intrinsic cells.
Arterioscler Thromb Vasc Biol
; 24(12): 2277-83, 2004 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-15486311
17.
Cardiomyocytes, endothelial cells and cardiac fibroblasts: S100A1's triple action in cardiovascular pathophysiology.
Future Cardiol
; 11(3): 309-21, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26021637
18.
Induction of microRNA-138 by pro-inflammatory cytokines causes endothelial cell dysfunction.
FEBS Lett
; 588(6): 906-14, 2014 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-24486907
19.
S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll-like receptor 4.
EMBO Mol Med
; 6(6): 778-94, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24833748
20.
MicroRNA-138 regulates hypoxia-induced endothelial cell dysfunction by targeting S100A1.
PLoS One
; 8(11): e78684, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24244340